Published ahead of print on October 3, 2003, doi:10.1165/rcmb.2003-0255OC
© 2004 American Thoracic Society DOI: 10.1165/rcmb.2003-0255OC Resident Murine Alveolar and Peritoneal Macrophages Differ in Adhesion of Apoptotic ThymocytesDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System; and Pulmonary and Critical Care Medicine Section, Medical Service, Department of Veterans Affairs Medical Center, Ann Arbor, Michigan; and Departments of Cellular and Molecular Physiology, Pediatrics, and Obstetrics and Gynecology, Penn State College of Medicine, Hershey, Pennsylvania Address correspondence to: Jeffrey L. Curtis, M.D., Pulmonary and Critical Care Medicine Section (111G), Department of Veterans Affairs Medical Center, 2215 Fuller Road; Ann Arbor, MI 48105-2303. E-mail: jlcurtis{at}umich.edu
Apoptotic cells must be cleared efficiently by macrophages (Mø) to prevent autoimmunity, yet their ingestion impairs Mø microbicidal function. The principal murine resident lung phagocyte, the alveolar Mø (AMø), is specifically deficient at apoptotic cell ingestion, both in vitro and in vivo, compared with resident peritoneal Mø (PMø). To further characterize this deficiency, we assayed static adhesion in vitro using apoptotic thymocytes and resident AMø and PMø from normal C57BL/6 mice. Adhesion of apoptotic thymocytes by both types of Mø was rapid, specific, and cold-sensitive. Antibody against the receptor tyrosine kinase MerTK (Tyro12) blocked phagocytosis but not adhesion in both types of Mø. Surfactant protein A increased adhesion and phagocytosis by AMø, but not to the levels seen using PMø. Adhesion was largely cation-independent for PMø and calcium-dependent for AMø. Adhesion was not inhibited in either Mø type by mAbs against ß1 or ß3 integrins or scavenger receptor I/II (CD204), but AMø adhesion was inhibited by specific mAbs against CD11c/CD18. Thus, resident murine tissue Mø from different tissues depend on qualitatively disparate receptor systems to bind apoptotic cells. The decreased capacity of murine AMø to ingest apoptotic cells is only partially explained by reduced initial adhesion.
Abbreviations: activation-induced cell death, AICD alveolar macrophage, AMø bronchoalveolar lavage, BAL fetal bovine serum, FBS human monocyte-derived macrophage, HMDM monoclonal antibody, mAb murine bone marrowderived macrophage, MBMDM peritoneal macrophage, PMø phosphatidylserine, PS PS receptor, PS-R
Efficient clearance of apoptotic cells by mononuclear phagocytes is essential to permit normal organogenesis, to maintain homeostasis of rapidly dividing tissues such as the bone marrow, and to terminate inflammatory responses gracefully (1). The rationale for efficiently clearing dying neutrophils or eosinophils is obvious, as their enzymes would be highly damaging if leaked as these cells progress to necrosis (2). Apoptotic T cells might seem less potentially damaging, but they are a potential source of nucleosomes, the macromolecular complexes that form the basic units of chromatin. Nucleosomes, which in vivo are formed exclusively by chromatin digestion during apoptosis, are a major immunogen for autoantibody production in systemic lupus erythematosus (3). Hence, impaired clearance of apoptotic T cells may break peripheral self-tolerance. Nevertheless, this clearance process comes at a potential price to host defense against pathogens, because macrophages (Mø) that ingest apoptotic cells actively and specifically downregulate their own capacity to produce inflammatory cytokines and mediators (4). This effect is mediated chiefly by transforming growth factor-ß1, with a lesser contribution by platelet-activating factor and prostaglandin E2 (4). The potential clinical relevance of this downregulation has been shown in a murine model of trypanosomiasis, in which ingestion of apoptotic T cells decreased Mø inflammatory cytokine production and parasite killing (5). Whether such downregulation is a problem during acute infections in most tissues is unclear. Although blood-derived monocytes appear to be unable to ingest apoptotic cells immediately upon recruitment (6, 7), contact with apoptotic cells alone may be sufficient in some circumstances to initiate an anti-inflammatory response (8). Hence, increased understanding of the process by which various cell types ingest their dying neighbors, and its consequences for host defense, is urgently needed. Clearance of apoptotic cells is particularly relevant to the lungs, where a significant fraction of lymphocytes recovered from the alveolar spaces of both normal mice and mice undergoing antigen-induced inflammation are apoptotic (9). Secretion of crucial proinflammatory cytokines could be suppressed if resident alveolar Mø (AMø) ingest dying T cells before or during encounters with pathogens. Thus, the lungs, a mucosal surface frequently exposed to pathogens, present a unique challenge in regulating clearance of apoptotic T cells. In fact, decreased phagocytosis of apoptotic leukocytes by resident lung Mø has been demonstrated in three species. The phenomenon was first identified in phagocytosis of apoptotic neutrophils by resident rabbit AMø, relative to inflammatory Mø recovered from rabbit lungs (6). We reported markedly decreased phagocytosis of apoptotic thymocytes, which were used as a model of clearance of lymphocytes undergoing activation-induced cell death (AICD), by resident murine AMø relative to resident murine peritoneal Mø (PMø) (10). This defect was seen both in vitro in seven murine strains and in vivo, and was specific for apoptotic cells (as opposed to three other phagocytic targets), and extended to apoptotic neutrophils (10, 11). Importantly, the phagocytic defect in AMø could not be explained by differences in expression of several Mø receptors previously implicated in phagocytosis of apoptotic cells, including ß1 and ß3 integrins (10). Human AMø also show reduced apoptotic cell ingestion (12). Defining the basis of this deficit could provide key insights into the molecular mechanisms underlying Mø clearance of apoptotic cells. We subsequently found that both AMø and PMø appear to share many downstream signaling pathways required for apoptotic cell ingestion (11), leaving the mechanism for the AMø phagocytic defect undefined. More recently, we showed that both types of Mø express the stereospecific receptor for phosphatidylserine (PS-R) (13), and that mAb against PS-R profoundly inhibited phagocytosis but not adhesion of apoptotic cells by both AMø and PMø (14). We also found that at least a portion of the decreased ingestion of apoptotic cells by murine AMø can be attributed to markedly decreased expression of protein kinase C isoform ß II, which we proved to be uniquely required for this process in both types of Mø (14). However, it remained uncertain whether this difference was the sole explanation of the AMø functional deficiency. The purpose of the current study was to investigate whether differences between AMø and PMø in adhesion of apoptotic thymocytes could also contribute to the difference in phagocytosis, and to characterize the binding interaction in vitro. Because we have previously shown that AMø have a similar defect in phagocytosis of apoptotic thymocytes, lymphocytes, and neutrophils (10), we used apoptotic thymocytes as a convenient model of T cells dying by AICD. We found that both types of Mø rapidly and specifically bound apoptotic thymocytes, but that the pronounced differences between AMø and PMø in the kinetics of adhesion and the dependence on Ca++ and ß2 integrins indicate that the two cell types use disparate receptor systems.
Antibodies The following mAbs were purchased from PharMingen (San Diego, CA): M17/4 (anti-murine CD11a; rat IgG2a, ); M1/70 (anti-murine CD11b; rat IgG2b, ); HL3 (anti-murine CD11c; Armenian hamster IgG1, ); C71/16 (anti-murine CD18; rat IgG2a, ); M18/2 (anti-murine CD18; rat IgG2a, ); GAME-46 (anti-murine CD18; rat IgG1, ); Ha2/5 (anti-murine CD29; Armenian hamster IgM, ); R1-2 (anti-murine CD49 d; rat IgG2b, ); 5H1027 (anti-murine CD49e; rat IgG2b, ); H9.2B8 (anti-murine CD51; Armenian hamster IgG1, ); 2C9.G2 (anti-murine CD61; Armenian hamster IgG1, ); R3-34 (control rat IgG1, ); R3595 (control rat IgG2a, ); A95-1 (control rat IgG2b, ) G2352356 (control Armenian hamster IgG1, ); A194 (control hamster IgG3. ); A19-3 (control hamster IgG1, ); G2351(control hamster IgM). mAb 2F8 (rat IgG2b) against the murine scavenger receptor type I/II (CD204) was obtained from Serotec (Raleigh, NC) and polyclonal goat-anti-murine MerTK from R&D Systems (Minneapolis, MN).
Mice
Isolation and Culture of Mø
Isolation and Apoptosis Induction of Thymocytes
Adhesion Assays
Phagocytosis Assays
Flow Cytometry
Isolation of Surfactant Protein A
Purification of Recombinant Annexin V
Statistical Analysis
AMø and PMø Specifically Bind Apoptotic Thymocytes In Vitro, but Differ in Kinetics of Adhesion Both AMø and PMø bound apoptotic thymocytes, but the two types of Mø differed considerably, both in rate of adhesion and in the maximal percentage of Mø showing thymocyte binding (Figure 1). By 5 min, a majority of PMø had bound apoptotic thymocytes, and the number of apoptotic thymocytes bound per Mø continued to increase slightly throughout the 30-min assay. By contrast, the rate of binding by AMø rose more slowly to a lower plateau at 15 min, and the number of bound apoptotic thymocytes per AMø did not increase thereafter. The kinetic analysis was terminated at 30 min, a time that we had previously shown to correspond to the beginning of phagocytosis (10). Based on these results, plus those of additional control experiments (see online supplement), all subsequent assays were performed at 15 min of coincubation.
To definitively exclude a contribution of ingested cells, in control experiments we fluorescently labeled apoptotic cells before coincubating them with Mø, and quenched fluorescence at the end of coincubation using methylene blue. Quenching totally abolished fluorescence (data not shown), implying that at the time-point studied, all apoptotic cells were extracellular. Because the method we used to induce apoptosis produced early apoptotic cells that were not entirely PS-positive, we also considered the possibility that binding of viable thymocytes by the two Mø types was a potential confounding factor in our analysis. However, results of control experiments (see online supplement) indicated that adhesion of viable thymocytes and apoptotic thymocytes is independent, and that under the conditions used in our assay any potential interference by viable thymocytes in the mixture would be negligible.
SP-A Slightly Increases Adhesion of Apoptotic Thymocytes by Murine AMø
Similarly, SP-A slightly but significantly increased adhesion of apoptotic thymocytes to AMø (adhesion-positive AMø: control 65.6 ± 1.8% versus SP-A 74.1 ± 1.8%, n = 912; mean ± SEM, P < 0.005; adhesive index: control, 1.0 ± 0.1 versus SP-A, 1.5 ± 0.1, P < 0.001, unpaired t test), but had no significant effect on adhesion to PMø (adhesion-positive PMø: control, 90.8 ± 1.3% versus SP-A, 89.3 ± 1.0%, n = 912; mean ± SEM, P = 0.34; adhesive index, control, 3.0 ± 0.2 versus SP-A, 3.2 ± 0.1, P = 0.28, unpaired t test). To test the potential dependence of adhesion on serum proteins other than complement components, in control experiments we both induced thymocyte apoptosis and performed the adhesion assay in medium devoid of heat-inactivated FBS. Adhesion of apoptotic thymocytes in this assay was reduced in the absence of serum, but the effect was small (compared with assay in 10% serum, adhesion-positive Mø in serum-free conditions = 87.3 ± 1.3% of control for PMø and 80.8 ± 7.6% of control for AMø; mean ± SEM, n = 5, P < 0.05 for unpaired t test compared with assay in serum-containing medium). However, as shown by the adhesion index, the efficiency of adhesion to PMø was more sensitive to the absence of serum (compared with assay in 10% serum, adhesion index = 46.3 ± 7.6% of control for PMø versus 84.8 ± 7.8% of control for AMø versus; mean ± SEM, n = 5, P < 0.05 unpaired t test). Subsequent experiments were performed in medium containing heat-inactivated FBS unless otherwise specified.
MerTK Is Dispensable for Apoptotic Cell Adhesion In Vitro Pretreatment of Mø with anti-MerTK antibody (50 µg/ml) had no effect on adhesion of apoptotic thymocytes to either type of tissue Mø (Figures 3A and 3B). By contrast, anti-MerTK inhibited phagocytosis of apoptotic thymocytes, in both AMø and PMø, with a greater relative effect in PMø (Figures 3C and 3D), confirming the functional activity of the antibody. Thus, although these data provide novel confirmation of the importance of MerTK in Mø apoptotic cell phagocytosis, they do not explain the difference in adhesion between the two types of Mø.
Adhesion of Apoptotic Thymocytes by Resident Tissue Møs Is Cold-Inhibitable Some adhesive interactions, notably those mediated by lectin-carbohydrate interactions, are impervious to chilling; consequently, we next performed the binding assay for apoptotic cells on ice. Chilling to 4°C decreased adhesion substantially in both PMø and AMø (Figure 4). The degrees of inhibition induced by cold was similar in the two types of Mø (percent adhesion was suppressed 77.6 ± 5.8% in PMø, versus 85.1 ± 3.6% in AMø; P = 0.2821, unpaired t test comparing the two cell types; adhesive index was suppressed 91.9 ± 2.4% in PMø, versus 87.6 ± 3.3% in AMø; P = 0.2996, unpaired t test comparing the two cell types). Thus, a major component of adhesion of apoptotic cells by resident tissue Mø appears to require a change in conformation or membrane location of the involved receptors.
AMø Adhesion of Apoptotic Thymocytes Is Entirely Calcium-Dependent Studies of cation chelation and repletion disclosed a fundamental difference between resident murine AMø and PMø in apoptotic cell adhesion. We used EDTA, which binds Mg++ more effectively than Ca++, and EGTA, which potently chelates Ca++. EDTA slightly inhibited adhesion by PMø, and this effect was reversed by re-administration of Ca++ (Figure 5A). EGTA more markedly inhibited adhesion by PMø, and this effect was not reversed by readministration of Mg++. By contrast, adhesion of apoptotic thymocytes to AMø was almost totally abolished by cation chelation using either EDTA or EGTA. Readministration of Ca++ restored binding in AMø, whereas Mg++ did not (Figure 5B). These findings indicated that PMø were able to bind apoptotic thymocytes by both Ca++-dependent and cation-independent mechanisms, whereas binding of apoptotic thymocytes to AMø was entirely Ca++-dependent.
One receptor that potentially could be involved in the Ca++-independent component of Mø adhesion of apoptotic thymocytes is the murine scavenger receptor type I/II (CD204), which has been implicated in the phagocytosis of apoptotic cells (20). We tested the possible role of this receptor using the function-blocking mAb 2F8 (21), and Mø from BALB/c mice, because C57BL/6 mice have been reported to have a polymorphism in the gene for the scavenger receptor type I/II that eliminates the epitope recognized by mAb 2F8 (22). Incubation with mAb 2F8 at 30 µg/ml, which was a saturating concentration as confirmed by flow cytometry, had no significant effect on adhesion of apoptotic thymocytes to either type of Mø (adhesion-positive PMø: mAb 2F8, 83.7 ± 2.5% versus control IgG, 83.7 ± 2.6%; adhesion-positive AMø, mAb 2F8, 37.7 ± 4.8% versus control IgG, 37.6 ± 3.3%; adhesion index for PMø, mAb 2F8, 3.1 ± 0.2 versus control IgG, 2.8 ± 0.2; adhesion index for AMø, mAb 2F8, 0.5 ± 0.1 versus control IgG, 0.5 ± 0.1; mean ± SEM, n = 10, all comparisons P > 0.05, unpaired t test). Control experiments using the assay originally described by Fraser and colleagues (21) confirmed the ability of mAb 2F8 to totally inhibit Ca++-independent adhesion of both types of Mø to tissue-culture plastic in the presence of serum (data not shown). These data do not support an essential role for scavenger receptor A in apoptotic cell adhesion.
Binding of Apoptotic Thymocytes by AMø Is Inhibited by Blocking CD11c/CD18
However, examination of ß2 integrins showed an additional difference between the two types of tissue Mø. Adhesion to PMø was not inhibited by blocking the common ß2 integrin chain CD18 using mAb GAME-46 (Figure 6) or mAbs C71/16 and M18/2 (data not shown). Neither was adhesion to PMø inhibited by mAbs against the two
By contrast, adhesion to AMø was significantly inhibited by the anti-CD18 mAb, GAME-46, and to a somewhat lesser degree by mAb against one of the two chains with which CD18 pairs in resident AMø, CD11c (Figure 6). Flow cytometric analysis showed that the level of staining by GAME-46 was uniform among AMø, identical to expression by PMø, and identical to staining using two nonblocking anti-CD18 mAbs, C71/16 and M18/2 (data not shown), excluding the possibility that GAME-46 recognized an antigen found only on a subset of AMø. In separate experiments, phagocytosis of apoptotic cells by AMø was also inhibited by GAME-46 (compared with untreated control, the percent phagocytosis was suppressed 58.8 ± 1.4%, and the phagocytic index was suppressed 64.7 ± 2.4%).
The results of these studies indicate that resident murine Mø from two different tissues rapidly and specifically bind apoptotic thymocytes using mechanisms distinct from adhesion of viable thymocytes, but that AMø differ both qualitatively and quantitatively from PMø in this function. Similarities between the two types of Mø included inhibition of adhesion by chilling the cells to 4°C or by masking PS on the apoptotic cell using annexin V, and insensitivity to blocking ß1 or ß3 integrins. However, there were also notable differences between PMø and AMø in adhesion of apoptotic thymocytes. Compared with adhesion of apoptotic thymocytes to PMø, adhesion to AMø was much less rapid, somewhat less sensitive to the absence of serum, and characterized by markedly lower maximal binding. Adhesion was largely cation-independent in PMø, but almost totally calcium-dependent in AMø. Moreover, a major component of adhesion by AMø depended on CD11c/CD18, a ß2 integrin not expressed by resident PMø, whereas adhesion by PMø was independent of ß2 integrins. These novel findings provide further support for the possibility that the disparity between resident AMø and PMø in recognition of apoptotic cells may be an evolutionary adaptation of teleologic value because it preserves the crucial surveillance and microbicidal functions of AMø against autocrine downregulation (1, 4, 5, 23). This study also showed that the receptor tyrosine kinase MerTK did not mediate Mø adhesion of apoptotic cells, and that addition of SP-A did not correct the relative deficiency of murine AMø in adhesion and phagocytosis of apoptotic thymocytes to the levels seen in resident murine PMø. Results of our chelation and ß2 integrinblocking experiments indicate the existence of at least two distinct pathways of apoptotic cell adhesion to resident tissue Mø. PMø exhibited both a major cation-independent pathway and a minor calcium-dependent pathway, whereas AMø essentially showed only a calcium-dependent pathway that is partially explained by binding via CD11c/CD18. Absence of cation-independent adhesion is a partial explanation for the relative defect in phagocytosis by AMø, because 3050% of AMø do not interact with apoptotic thymocytes at all. Importantly, the performance of PMø in this short-term adhesion assay very closely paralleled the phagocytosis data we have previously reported (10), indicating a close functional linkage between adhesion and ingestion in this cell type. By contrast, a much greater percentage of AMø bound at least one apoptotic thymocyte (maximum adhesion = 5070%, current study) than ingested any apoptotic thymocytes (maximum phagocytosis = 19.1 ± 1.0% positive at 90 min) (10). Thus, although initial adhesion must constitute an obligatory step in phagocytosis, adhesion itself did not appear to be the rate-limiting step in the process for the majority of AMø that do bind apoptotic thymocytes. Why many of the remaining AMø that bind apoptotic cells do not go on to ingest any is uncertain, although post-receptor defects in signal transduction, such as the markedly reduced expression of PKC ßII in murine AMø (14), probably contribute. The current results using purified human SP-A agree with the previous findings of Schagat and coworkers (17) and Vandivier and colleagues (18) with regard to the effect on AMø phagocytosis, and extend them by analysis of adhesion and by comparison with resident murine Mø from another anatomic site. Like those investigators, we found 160300% increases from control values of either percent of phagocytic Mø or phagocytic index (although the absolute value of the phagocytic index we report is lower by a factor of 100 due to a difference in the method of calculation). Importantly, however, even on addition of SP-A, phagocytosis by AMø remained markedly reduced relative to that of PMø. These persistent differences between the two types of Mø argue that the selective defect we and others reported in resident AMø phagocytosis of apoptotic cells (6, 11) is not due simply to a unique requirement for bridging surfactant proteins absent from the in vitro assay, as has been suggested (24). The results presented here also extend our previous observation that resident murine AMø and PMø do not require RGDS-inhibitable integrins for phagocytosis (10). By contrast, previous studies have shown that human monocyte-derived Mø (HMDM) and MBMDM do use these systems (7, 25, 26). An obvious experimental difference between our system and those studies is the duration of culture before analysis: 6 h in our studies versus 57 d in the latter. This longer culture period is necessary because the precursors of HMDM and MBMDM lack the capacity to ingest apoptotic cells (6, 7), which can, however, be induced by cytokine stimulation (27). Because the receptor systems identified in studies of HMDM and MBMDM are also likely to be used by activated mononuclear phagocytes at sites of inflammation, results of those studies are nonetheless highly clinically relevant. The current analysis of constitutive clearance by resident mucosal Mø complements those studies by defining the mechanisms of normal physiologic clearance in the absence of inflammation. Our results also emphasize the importance of studying resident Mø from specific tissues. It is conceivable that still different physiologic behavior will be discovered in mononuclear phagocytes facing different burdens of apoptotic cells and different exposure to environmental challenges, as may be the case, for example, with microglial or retinal pigment epithelial cells, which reside behind the bloodbrain barrier, versus Kupffer cells, which are continuously exposed to bacterial products. Using a direct antibody blocking approach to examine the role of MerTK in apoptotic cell adhesion and phagocytosis, our results complement and extend the results of gene deletion of MerTK (19), which verified an essential role for MerTK in apoptotic cell clearance in vitro and in vivo. MerTK possesses dual extracellular immunoglobulin and fibronectin-type III motifs that suggest potential adhesive capacities (28). Hence, our finding that function-blocking Ab against MerTK did not block apoptotic cell adhesion may seem surprising. Nevertheless, it is likely that any strictly adhesive function of MerTK is dispensable due to the redundancy of Mø receptors that can mediate apoptotic cell adhesion. It is unlikely, but conceivable, that the polyclonal Ab we used failed to block epitopes essential for apoptotic cell adhesion although it could block phagocytosis. The apparent disparity between results of blocking PS expression on the apoptotic cells using annexin V in the current study (see online supplement), versus our previous finding that mAb 217 does not inhibit adhesion of apoptotic thymocytes (14), is explicable because PS can be bound in a stereo-nonspecific fashion by multiple receptors, including class B scavenger receptors, CD14, macrosialin (CD68), and thrombospondin-dependent vitronectin receptors (reviewed in Ref. 24). By coating the surface of the apoptotic cell densely, annexin V might antagonize adhesion via other receptors through steric hindrance, and hence be a highly effective inhibitor of both adhesion, and as we have previously shown, phagocytosis (10). It is formally possible from our collective data that the residual level of apoptotic cell phagocytosis by PMø that is not inhibited by mAb 217 (14) results from the calcium-independent adhesive activity possessed by PMø but absent from AMø (Figure 4), and that the receptor(s) mediating this binding can trigger phagocytosis without involvement of surface PS recognition. Unfortunately, this possibility cannot be tested directly by assaying phagocytosis in the presence of combined blockade using annexin V and mAb 217 without or with calcium chelation, because binding of annexin V to PS is also calcium-dependent. However, because mAb 217 also incompletely inhibits phagocytosis by AMø, which clearly lack calcium-independent adhesion, we favor the interpretation that this mAb is simply an imperfect functional antagonist of phagocytosis. A role for CD11c/CD18 in apoptotic cell recognition via C3bi in HMDM was previously shown by Mevorach et al (29), who employed an assay in the presence of fresh autologous serum to provide functional complement components. The difference in our assay system, which uses heat-inactivated serum, implies that we are detecting a complement-independent function of CD11c/CD18, as does the absence of effect of blocking CD11b/CD18 in PMø. Therefore, our results do not disagree with those of Mevorach et al. At face value, our results using viable thymocytes (see online supplement) appear to differ from those of Duvall and associates, who found that 64% of PMø bound viable thymocytes (30), whereas we found virtually no binding of viable thymocytes by either type of Mø. This difference undoubtedly results from the difference in the assay conditions, which in their case involved incubation for 2 h at 4°C. Because our experiments were not performed in a manner that would facilitate detection of lectin-mediated interactions, the current results should not be construed to call into question the substantial body of data indicating a role for carbohydrate recognition in apoptotic cell clearance (3032). In summary, we show rapid and specific adhesion of apoptotic thymocytes by resident murine tissue Mø, provide evidence that resident Mø in different organs use disparate adhesion systems, and have identified a receptor, CD11c/CD18, that mediates apoptotic cell adhesion in murine AMø. The collective findings of this study and our previous data (10, 14) in this system support a model of apoptotic cell recognition by mononuclear phagocytes that distinguishes between receptors that mediate initial adhesion and those that trigger phagocytosis (33, 34). Recognition of surface PS expression on the apoptotic cell appears to be central to this process, yet we have shown that neither the stereo-specific PS-R itself nor MerTK, which also binds PS via the soluble intermediaries Gas6 (35) or protein S (36, 37), are required for adhesion. It is plausible that some of the Mø molecules involved in apoptotic clearance serve both adhesive and informational functions, much in the manner of costimulatory activity by a variety of receptors during T cell activation. Because selective modulation of apoptotic cell clearance may be of therapeutic value in a wide variety of diseases, it will be important to define the unique aspects of this process used by Mø in different organs.
The authors thank Drs. Valerie Fadok, Peter Henson, Glenn Matsushima, and all the members of the Ann Arbor VA REAP for helpful suggestions and discussion; Drs. Mani Kavuru and Mary Jane Thomassen for performing BAL on alveolar proteinosis patients and Xiaoxuan Guo for technical assistance with SP-A preparation; Joyce O'Brien for secretarial support; and Drs. Robert Paine III and Antonello Punturieri for critiquing the manuscript. This study was supported by RO1 HL56309, RO1 HL6157, and R37 HL34788 from the USPHS; by Merit Review funding and a Research Enhancement Award Program (REAP) grant from the Department of Veterans Affairs; and by funding from the Michigan Life Sciences Initiative.
Portions of this work have been presented previously at the Autumn Immunology Conference, Chicago, IL, November 20, 2000, and at the International Conference of the American Thoracic Society, San Francisco, CA, May 20, 2001, and have been published in abstract form (Am. J. Respir. Crit. Care Med. 2001; 163:A187). This article has an online data supplement, which is accessible from this issue's table of contents online at www.atsjournals.org Received in original form July 5, 2003 Received in final form September 25, 2003
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||